Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi

Clinical trial NCT04042025 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04042025
Sponsor: Novartis Gene Therapies
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Spinal Muscular Atrophy Type I Spinal Muscular Atrophy Type II Spinal Muscular Atrophy Type III SMA

Start date: 2020-02-10
Primary completion: 2035-12-31
Enrollment: 85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.